Tag: antipsychotics and schizophrenia
An interview with Sir Robin Murray, who is a Professor of Psychiatric Research at the Institute of Psychiatry. He is perhaps best known for helping to establish the neurodevelopmental hypothesis of schizophrenia, and for his work on the environmental risk factors relating to schizophrenia.
Adults in the U.S. diagnosed with “serious mental illness” die on average 25 years earlier than others. This is not controversial, as establishment psychiatry and its critics agree. What is controversial is who is to blame?
The annual meeting of the UK’s Royal College of Psychiatrists is in full swing at the moment in London. The conference will again not be debating important new findings about antipsychotic drug treatment. Two years ago the conference organising committee rejected a suggestion to discuss this issue. This year I proposed a similar symposium. The proposal was rejected again. I am extremely concerned that the Royal College conference organising committee do not appear to be aware of the importance of this issue.
This week Live & Learn launched a research study on the experience of people labeled with mental disorders who have tried to stop taking psychiatric medications. This project -- the Psychiatric Medication Discontinuation/Reduction (PMDR) Study -- aims to understand the process of coming off psychiatric medications in order to better support those who choose to do so. The study seeks to answer the question: What helps people stop their psychiatric medications? What gets in the way of stopping?
A new study to be published in the next issue of Schizophrenia Research examines patients suffering from a first-episode of psychosis who stop taking any antipsychotic drugs. The researchers attempt to identify variables that can serve as predictors of the successful discontinuation of antipsychotics. They find, for example, that those who discontinue the drugs have, on average, the same outcomes as those who stay on them, and that those who have better social integration are more likely to discontinue without relapse.
In a study published yesterday, researchers from the Nippon Medical School in Tokyo bring attention to a condition known as neuroleptic-induced deficit syndrome (NIDS)...
Dr. Mickey Nardo adds to the ongoing discussion about the RAISE study results. He writes: “If there is ‘spin’ in the reporting of this study, we need to know about it. I personally think that it’s more important for RAISE to be reported completely and honestly than whether it comes out like they [or I] want it to come out. We don’t need some sanitized version of RAISE to tell us we need to turn our attention to a full bodied approach to the treatment of First Episode psychotic patients. We all already know that. What we do need is to have our confidence restored in our research community – that they will honestly and clearly report their findings whether they are clean as a whistle or an unholy mess.”